| Description | Danicopan (ACH-4471) (ACH-4471) is a selective, orally active small molecule factor D inhibitor with high binding affinity to human factor D, with a Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits the activity of the complement replacement pathway (APC) and may block the complement replacement pathway in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). |
| In vitro | Danicopan (ACH-4471) inhibits the proteolytic activity of purified factor D and its natural substrate factor B binding to C3b, blocking the production of Bb fragments in a dose-dependent manner, with an IC50 value of 0.015 μM. Danicopan (ACH-4471) effectively inhibits hemolysis with IC50 values from 0.0040 μM to 0.027 μM (IC90 values from 0.015 μM to 0.11 μM). |
| Target activity | FD:(kd)0.54 nM |
| Synonyms | ACH-4471 |
| molecular weight | 580.41 |
| Molecular formula | C26H23BrFN7O3 |
| CAS | 1903768-17-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 260 mg/mL (447.96 mM), Sonication is recommended. |
| References | 1. Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102(3):466-475. |